The economic burden of chronic obstructive pulmonary disease in the elderly: Results from a systematic review of the literature

Current Opinion in Pulmonary Medicine

Volumn 17, Issue SUPPL. 1, 2011, Pages

  Bustacchini, Silvia ^a   Chiatti, Carlos ^a   Furneri, Gianluca ^a   Lattanzio, Fabrizia ^a   Mantovani, Lorenzo G ^b  

^a INRCA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

chronic obstructive pulmonary disease; direct costs; elderly; exacerbations

Indexed keywords

ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; TIOTROPIUM BROMIDE; XANTHINE;

ANTICHOLINERGIC EFFECT; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE SEVERITY; DRUG COST; DRUG MECHANISM; ECONOMIC ASPECT; ELDERLY CARE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITAL COST; HOSPITALIZATION; HUMAN; LONG TERM CARE; MEDLINE; REVIEW; UNITED STATES;

AGED; COMORBIDITY; COST OF ILLNESS; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MALE; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; UNITED STATES;

EID: 84855413793     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/01.mcp.0000410746.82840.79     Document Type: Review

References (23)

1. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2010. http://www.goldcopd.org/[accessed 15 September 2011].
2. Global status report on noncommunicable diseases 2010. Geneva: World Health Organization; 2011. http://www.who.int/nmh/publications/ncd-report-full- en.pdf [accessed 15 September 2011].
3. Zweifel P, Felder S, Meiers M. Ageing of population and healthcare expenditure: a red herring? Health Econ 1999; 8:485-496. (Pubitemid 29462240)
4. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Healthcare Programmes, Oxford: Oxford University Press; 1997.
5. Database of historical inflation rates (consumer prices). http://www.index mundi.com [accessed 15 September 2011].
6. Database of historical currency conversion. http://www.xe.com/[accessed 15 September 2011]
7. Dalal AA, Petersen H, Simoni-Wastila L, Blanchette CM. Healthcare costs associated with initial maintenance therapy with fluticasone propionate 250mg/salmeterol 50mg combination versus anticholinergic bronchodilators in elderly US Medicare-eligible beneficiaries with COPD. J Med Econ 2009; 12:339-347.
8. Blanchette CM, Broder M, Ory C et al. Cost and utilization of COPD and asthma among insured adults in the US. Curr Med Res Opin 2009; 25:1385-1392.
9. Gerdtham UG, Andersson LF, Ericsson A et al. Factors affecting chronic obstructive pulmonary disease (COPD)-related costs: a multivariate analysis of a Swedish COPD cohort. Eur J Health Econ 2009; 10:217-226.
10. Menzin J, Boulanger L, Marton J et al. The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population. Respir Med 2008; 102:1248-1256.
11. Goodridge D, Lawson J, Duggleby W et al. Healthcare utilization of patients with chronic obstructive pulmonary disease and lung cancer in the last 12 months of life. Respir Med 2008; 102:885-891.
12. Blanchette CM, Gutierrez B, Ory C et al. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population. J Manag Care Pharm 2008; 14:176-185. (Pubitemid 351453818)
13. de Miguel Diez J, Carrasco Garrido P, Garc?́a Carballo M et al. Determinants and predictors of the cost of COPD in primary care: a Spanish perspective. Int J Chron Obstruct Pulmon Dis 2008; 3:701-712.
14. Simon-Tuval T, Scharf SM, Maimon N et al. Determinants of elevated healthcare utilization in patients with COPD. Respir Res 2011; 12:7.
15. Fuhrman C, Roche N, Vergnenè gre A et al. Hospital admissions related to acute exacerbations of chronic obstructive pulmonary disease in France, 1998-2007. Respir Med 2011; 105:595-601.
16. Geitona M, Hatzikou M, Steiropoulos P et al. The cost of COPD exacerbations: a university hospital-based study in Greece. Respir Med 2011; 105:402-409.
17. Chi MJ, Lee CY, Wu SC. The prevalence of chronic conditions and medical expenditures of the elderly by chronic condition indicator (CCI). Arch Gerontol Geriatr 2011; 52:284-289.
18. Dalal AA, Shah M, D'Souza AO, Rane P. Costs of inpatient and emergency department care for chronic obstructive pulmonary disease in an elderly Medicare population. J Med Econ 2010; 13:591-598.
19. Gibson PG, McDonald VM, Marks GB. Asthma in older adults. Lancet 2010; 376:803-813.
20. Castaldi PJ, Rogers WH, Safran DG, Wilson IB. Inhaler costs and medication nonadherence among seniors with chronic pulmonary disease. Chest 2010; 138:614-620.
21. Hutchinson A, Brand C, Irving L et al. Acute care costs of patients admitted for management of chronic obstructive pulmonary disease exacerbations: contribution of disease severity, infection and chronic heart failure. Intern Med J 2010; 40:364-371.
22. Simoni-Wastila L, Blanchette CM, Qian J et al. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities. Am J Geriatr Pharmacother 2009; 7:262-270.
23. Foster TS, Miller JD, Marton JP et al. Assessment of the economic burden of COPD in the U.S.: a review and synthesis of the literature. COPD 2006; 3:211-218. (Pubitemid 44949061)